The benefits of deep brain stimulation for treating substance use disorders remain uncertain amid inconsistent results for this surgical implant intervention.

DBS is a surgical procedure that uses implanted electrodes to send electrical signals to targeted areas in the brain, interrupting abnormal neural activity. It may be implemented when medications lose effectiveness or cause disruptive side effects.

Although brain-computer interfaces can help people recover lost functions and allow direct brain-to-computer communication in the future, surveys have shown little public support for using them to boost abilities like memory or focus in healthy people.

These devices can accurately forecast neurological events like seizures and suggest or even automatically deliver responses. Their constant monitoring and prescriptive functions may blur the line between patient choice and device influence.

Synchron's brain-computer interface, the Synchron Switch, takes advantage of preexisting medical devices, such as stents and catheters. Cells grow over the device over a 90-day period, incorporating it into the vessel wall and minimizing clots.

Most people with amyotrophic lateral sclerosis, or Lou Gehrig's disease, require assistance with daily life due to loss of motor control. The electrode-coated, stent-like device used motor mapping data and machine learning to translate brain activity into actions.

Although the substance is banned in the US, it's legal in Mexico. Americans who have traveled there for treatment, including the NFL's Braden Smith, say the drug helps deal with conditions like obsessive-compulsive disorder.

Several companies developing brain-computer interfaces have begun testing on humans with promising results. These implants have helped reanimate paralyzed limbs and enable communication, though ethical concerns remain about data privacy.

Companies like Neuralink are experimenting with volunteers who have lost control over their bodies. Many of the program's participants claim the most significant benefit from the tool is the ability to perform simple, mundane tasks, such as playing video games or shaking hands, rather than more obvious milestones like walking or eating. This essay explores what it's like, day to day, to use a brain implant.

Despite providing relief from neurological conditions, patients are left stranded when the companies that make these devices shut down. The lack of regulation means patients often face technical failure, insurance battles, or risky surgeries to maintain their quality of life.

This article explores whether the therapeutic potential of psychedelic drug use is really as good as current research suggests. Scientists are exploring its applications for conditions ranging from the existential crisis that can accompany terminal diagnoses to chronic mental health conditions, including anxiety and PTSD.

A clinical trial participant with severe epilepsy described becoming “one” with her implant after it gave her unprecedented control over her seizures. When the device was removed due to the company shutting down, she experienced deep emotional trauma and a sense of personal loss.

When opioids enter the brain, they dock in receptors, blocking electrical pulses such as those that communicate pain. They also trigger the release of dopamine, a neurotransmitter tied to motivation and associated with stress relief.

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain.

A helpful resource from the National Institute on Drug Abuse (part of the NIH). This article examines addiction treatment and recovery through the science behind several accepted methods. The guide draws helpful comparisons with other chronic disease treatments. In particular, it discusses the overlap between medications and therapeutic treatments, and the understanding that relapse doesn’t indicate treatment failure—only a need for continued or modified care.

How magical are magic mushrooms, at least where depression is concerned? Some 24 volunteers participated in a study to evaluate the efficacy of using psilocybin in combination with psychotherapy to treat individuals suffering from depression. While some controversies remain about its use—psilocybin is known to cause psychosis sometimes—some scientists think the benefits outweigh the risks.

The man had sought out the drug to help him overcome his substance abuse disorder. Though anecdotal reports indicate potential promise, there's been no large-scale clinical trials on ibogaine's safety and efficacy. The plant is derived from a root bark named iboga and has been used for centuries by indigenous communities in Gabon, but first entered scientific consciousness in 1901 after its alkaloid was isolated from Iboga.

The country green lighted the treatments for July 1, 2023, onward, with MDMA—ectasy—as a post-traumatic stress disorder treatment, and psilocybin—magic mushrooms—as an option for people with treatment-resistant depression.

As one of twelve test subjects in Neuralink's PRIME study, Rob Greiner's implant translates his brain's activity into digital commands for the 'Battlefield 6' game. He can now also design 3D models and 3D-print objects using his thoughts.

Research shows that psychedelics may induce something called "critical periods" in the adult brain, which can make our brains more open to learning and changing, like they once were back in early childhood. Psychedelics similarly change how social creatures like octopuses behave, which demonstrates that these animals could help us better understand our own neurobiology.

Unlike traditional prosthetics that rely on surface electrodes or mechanical parts, this system uses implanted titanium and nerve-connected electrodes to enable a seamless brain-to-arm connection. Patients train in virtual reality with their implanted signals before using the physical prosthesis.

A study led by a team from Stanford University showed that MR can help people with depression by providing pathways to engage in activities such as digital board games and dancing. Participants saw reduced symptoms of depression that made their overall treatment plans more successful.

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

Clinical trials showed a 44% reduction in risk for recurrence of SAD for those who took the drug compared to a placebo group. Bupropion is a norepinephrine–dopamine reuptake inhibitor, which increases dopamine (other common antidepressants, known as selective serotonin reuptake inhibitors, sometimes can suppress dopamine, but not always).

Brain organoid research is enabling researchers to study distinct electrical firing patterns associated with schizophrenia. These "mini-brains" that are constructed in the lab from patients' cells could lead to better diagnosis approaches and drug development.

Brain imaging shows that ayahuasca, MDMA, DMT, and psilocybin profoundly affect neural activity, giving rise to higher states of introspection and consciousness. This article details exactly how each of these drugs physically affects the brain and what that means for mental health treatment. Some of these drugs quiet the brain or trigger the release of neurochemicals associated with mood regulation and learning.

The nature of consciousness—what it is, where it comes from, and how it manifests as moment-to-moment experience—remains under debate by scientists. Recent studies show psychedelics were found to boost low-frequency brain signals known as delta waves, a behavior also seen during dream states.